Ruparelia Neil, Prendergast Bernard D
a 1Oxford Heart Centre, John Radcliffe Hospital , Oxford, UK.
b 2St Thomas' Hospital , London, UK.
Minim Invasive Ther Allied Technol. 2015;24(5):264-73. doi: 10.3109/13645706.2015.1031680. Epub 2015 Mar 31.
Aortic stenosis (AS) is the most common valvular pathology and its prevalence is expected to increase rapidly in coming decades as a consequence of the increasingly elderly population. Without treatment, severe symptomatic AS has a very poor prognosis with a mortality of 50% at two years. Whilst surgical aortic valve replacement is the gold standard treatment, a significant minority of patients are deemed inoperable and declined surgery due to prohibitively high risk. The advent of transcatheter aortic valve implantation (TAVI) has revolutionised their treatment. In this review, we discuss current indications for TAVI, other applications of this technology and future indications.
主动脉瓣狭窄（AS）是最常见的瓣膜病变，随着人口老龄化加剧，预计在未来几十年其患病率将迅速上升。未经治疗的重度症状性AS预后很差，两年死亡率达50%。虽然外科主动脉瓣置换术是金标准治疗方法，但相当一部分患者因手术风险极高而被视为无法手术并拒绝手术。经导管主动脉瓣植入术（TAVI）的出现彻底改变了他们的治疗方式。在本综述中，我们讨论了TAVI的当前适应证、该技术的其他应用以及未来适应证。
